Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Response crawled time : 16:20 save search
Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
Published: 2023-10-21 (Crawled : 16:20) - globenewswire.com
HARP | $23.01 0.07% 6.6M
|
Health Technology
| Email alert
Add to watchlist
hpn328 congress cell trial therapeutics response
Gracell Biotechnologies Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkin’s Lymphoma at EHA2023, Highlighting 100% Overall Response Rate
Published: 2023-06-10 (Crawled : 16:20) - globenewswire.com
GRCL | $10.25 -0.29% 6.4M
|
Manufacturing
| Email alert
Add to watchlist
gc012 response results
AbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® (risankizumab) in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor Therapy
Published: 2023-03-18 (Crawled : 16:20) - prnewswire.com
ABBV | $161.67 -0.38% -0.04% 5.4M
|
Health Technology
| Email alert
Add to watchlist
il-17 skyrizi abbvie psoriasis response therapy results study
New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia
Published: 2022-12-10 (Crawled : 16:20) - prnewswire.com
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
| Email alert
Add to watchlist
FNCTF | $11.128 -20.84% 580
|
Communications
| Email alert
Add to watchlist
imbruvica treatment glow leukemia response plus results study
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
Published: 2022-06-25 (Crawled : 16:20) - globenewswire.com
SNYNF | $92.9 -2.18% 880
|
Health Technology
| Email alert
Add to watchlist
BNTX | $87.88 1.62% 1.59% 750K
|
Health Technology
| Email alert
Add to watchlist
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
| Email alert
Add to watchlist
FNCTF | $11.128 -20.84% 580
|
Communications
| Email alert
Add to watchlist
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
| Email alert
Add to watchlist
covid-19 vaccine response
Results of Novel Clinical Study Show Adults with Moderately to Severely Active Ulcerative Colitis Achieved Higher Rates of Clinical Response, Clinical Remission, and Endoscopic Improvement at 12 Weeks with Guselkumab and Golimumab Combination Therapy Versus Either Monotherapy Alone
Published: 2022-02-19 (Crawled : 16:20) - prnewswire.com
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
| Email alert
Add to watchlist
response active one therapy pons results ulcerative colitis
New Clinical Responses for AGEN1181 Presented at AACR
Published: 2021-04-10 (Crawled : 16:20) - globenewswire.com
AGEN 4 | $6.495 -20.31% -25.48% 1.5M
|
Health Technology
| Email alert
Add to watchlist
presentation response
Theratechnologies Announces New Data Demonstrating Tesamorelin’s Positive Effect on Immune Response Linked to Liver Inflammation
Published: 2021-03-20 (Crawled : 16:20) - globenewswire.com
THTX | $1.33 -6.34% -6.77% 58K
|
Health Technology
| Email alert
Add to watchlist
positive liver response
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.